Israeli researcher Raphael Mechoulam has announced the development of a process to modify and stabilize cannabidiolic acids (CBDA) that appear early in the cannabis plant’s growth, rendering compounds that have the potential for large-scale use.
The result is a semi-synthetic, fully stable, acid-based compound that could be useful in suppressing nausea from chemotherapy, and be a treatment for such afflictions as Inflammatory Bowel Disease (IBD) and Psoriasis.
Researchers say such compounds, which are more potent than CBD or THC – and which so far have shown no negative side effects – could replace steroids and opioids.
Politically correct for pharma
Mechoulam worked with American biotech startup EPM to develop the solution to stabilizing the acids through esterification, a simple chemical process. That could prove interesting to the pharmaceutical industry as the process turns out the acids in a consistent form that is patentable. Also, EPM CEO Reshef Swisa said the U.S. Food and Drug Administration has told the company the compound would not be treated as cannabis but as any other drug in development, thereby avoiding the stigma and legal limitations associated with marijuana.